Table 3.
Improvement rates of gastroesophageal reflux symptoms at four and eight weeks.
| Symptom Improvement |
Week 4 | Week 8 | ||||
|---|---|---|---|---|---|---|
| Esomeprazole | Esomeprazole + Mosapride | p Value | Esomeprazole | Esomeprazole + Mosapride | p Value | |
| Intention-to-treat set | ||||||
| Number of patients | 30 | 30 | 30 | 30 | ||
| Total symptom | 11 (36.7) | 14 (46.7) | 0.600 | 24 (80.0) | 23 (76.7) | 1.000 |
| Heartburn | 2 (6.7) | 3 (10.0) | 1.000 | 21 (70.0) | 22 (73.3) | 1.000 |
| Regurgitation | 4 (13.3) | 3 (10.0) | 1.000 | 22 (73.3) | 18 (60.0) | 0.637 |
| Dyspepsia | 2 (6.7) | 2 (6.9) | 1.000 | 22 (73.3) | 18 (60.0) | 0.092 |
| Per-protocol set | ||||||
| Number of patients | 29 | 26 | 29 | 26 | ||
| Total symptom | 10 (34.5) | 10 (38.5) | 0.980 | 23 (79.3) | 19 (73.1) | 0.822 |
| Heartburn | 2 (6.9) | 1 (3.8) | 1.000 | 21 (72.4) | 18 (62.1) | 1.000 |
| Regurgitation | 4 (13.8) | 1 (3.8) | 0.506 | 22 (75.9) | 14 (53.8) | 0.279 |
| Dyspepsia | 2 (6.9) | 1 (3.8) | 1.000 | 21 (72.4) | 15 (57.7) | 0.096 |
Data are presented as number (%).